Receptor-mediated catabolism of low density lipoprotein (LDL) by cultured cells depends on the presence of functionally significant arginine and lysine residues on the lipoprotein apoprotein. When these are blocked, the recognition process is abolished, and catabolism of the modified lipoprotein is restricted to other mechanisms. Accurate discrimination between the activities of the receptor and nonreceptor pathways in vivo depends critically on the metabolic properties of this chemically modified lipoprotein. Here we report our experiences with two lysine-modified LDL tracers, glucosylated LDL (GLC-LDL) and 2-hydroxyacetaldehyde-treated LDL (HOET-LDL). The fractional clearance rate of GLC-LDL (0.25 ± 0.05 pools/day, n = 5) was 50% of that of control material (0.51 ± 0.09 pools/day) injected simultaneously into normal subjects. The HOET-LDL was also retarded in its clearance. Here, however, the fractional clearances of the control (0.37 ± 0.06 pools/day, n = 6) and modified lipoprotein (0.19 ± 0.03 pools/day) were lower than those obtained by the glucosylation procedure. We suspect that the prolonged incubation required for glucosylation of LDL artifactually accelerated its catabolism. The HOET-LDL does not suffer from this defect and seems to be a better tracer of the receptor-independent pathway. In a group of 10 subjects, HOET-LDL was metabolically indistinguishable from 1,2 cyclohexanedione-treated, arginine-modified LDL. (Arteriosclerosis 4:604-613, November/December 1984) L ow density lipoprotein (LDL) catabolism occurs by at least two distinct pathways. 1 One of these is an autoregulated system responsible for the controlled delivery of LDL cholesterol to cells.
L ow density lipoprotein (LDL) catabolism occurs
by at least two distinct pathways. 1 One of these is an autoregulated system responsible for the controlled delivery of LDL cholesterol to cells. 2 The key component of this pathway is a high affinity receptor located on the cell surface membrane. It binds LDL and promotes its rapid transfer into the cell in endocytic vesicles. The lipoprotein is transported to lysosomes for degradation, while the receptor recycles to the cell surface to initiate further internalization. 3 The specificity of the receptor-lipoprotein interaction on the cell membrane is dependent on an electrostatic attraction between positively charged residues of ar-ginine 4 or lysine 5 on the lipoprotein apoprotein and complementary negative domains (as yet undefined) on the receptor. It is possible to abolish this interaction by selective modification of LDL at the critical arginine or lysine residues. Catabolism of the modified lipoprotein in vivo is therefore presumably restricted to pathways that do not involve the high affinity receptor and whose nature and locations are not yet identified.
In earlier studies we used a chemical modification procedure to measure the contributions made by the receptor and nonreceptor mechanisms to human LDL catabolism. We used 1,2 cyclohexanedione (CHD) to block the guanido group of arginyl residues on LDL apoprotein (apo LDL), and found that the receptor pathway accounted for between 35% and 50% of LDL catabolism in normal subjects. 6 ' 7 This value was reduced in familial hypercholesterolemic patients 68 whose cell membrane receptors for LDL are defective or absent. The use of the CHD-LDL probe, however, was open to the criticism that the modification is unstable. In vitro incubation of the modified lipoprotein resulted in the partial restoration of its ability to bind to the membranes of cultured fibroblasts. 9 ' 10 However, our in vivo studies did not show that the modified tracer was degraded via the receptor pathway. 10 Recently we and others have used lysine modifying agents which produce chemically stable derivatives. The method of choice is to block the lysine residue by the reductive methylation procedure described by Means and Feeney. 11 This delays the plasma clearance of the lipoprotein in some animals (rabbits, 10 monkeys, 9 and rats 9 ); but in humans we found that the catabolism was accelerated, which suggests that the probe was recognizably foreign. 10 Several groups have reported 12 -14 that apo LDL is subject to glucosylation at the epsilon amino groups of its lysine residues by a mechanism analogous to that responsible for hemoglobin A te production. An in vitro incubation of LDL with glucose in the presence of an appropriate reducing agent produces a stable glucosylated derivative (GLC-LDL) that can no longer bind to high affinity LDL receptors.
12 -14 GLC-LDL might, therefore, be an alternative probe to assess receptor-independent LDL catabolism, as recently proposed by Kesaniemi et al. 15 They found that GLC-LDL was cleared from the circulation more slowly than the control lipoprotein. Their data suggested that 80% of LDL catabolism was receptor-mediated, a result at variance with earlier estimates obtained by using CHD-LDL. In this report we examine the utility of GLC-LDL and compare its kinetic properties with those of hydroxyethylated LDL (HOET-LDL), a novel probe of the receptor-independent pathway.
Methods

Subjects
A group of 21 healthy volunteers (11 men, 10 women) gave informed consent to this study. Their ages, weights, and plasma lipid values are presented in Table 1 . Their body weights related to height were within 15% of the "ideal" values quoted by the Metropolitan Life Insurance Company, 16 and their plasma lipids (measured according to the Lipid Research Clinics Protocol 17 ) were within the reference values for our laboratory. Throughout the study, no subject was taking any medication (including the contraceptive pill), except potassium iodide (60 mg thrice daily), which was given for 3 days before and 1 month after the radioiodide injection to prevent its sequestration by the thyroid gland. The clinical and laboratory screenings showed no evidence of hepatic, renal, endocrine, or hematologic dysfunction. All subjects were outpatients; our previously published protocol 18 showed that this provided the steady-state conditions necessary for LDL kinetic studies. The plasma LDL cholesterol concentrations of all subjects varied less than 14% from the mean and their body weight fluctuated by less than 1 kg. The study met the requirements of the Human Ethics Committee of Glasgow Royal Infirmary.
Low Density Lipoprotein Isolation and Labeling
Approximately 100 ml of blood was collected from each subject after a 14-hour fast. The plasma was separated by low speed centrifugation, and was ap- 21 Unbound radioiodide and glycine were removed by gel filtration through a PD 10 column (Pharmacia, UK) followed by exhaustive dialysis against 0.15 M NaCI/0.01% Na^DTA (pH 7.0). This resulted in a product in which more than 97% of the radioactivity was precipitable with 10% trichloracetic acid and less than 4% was extractable into chloroform/methanol (2:1, vol/vol).
in the presence of 80 mM glucose and 80 mM sodium cyanoborohydride at 37° C for 7 days. During this time, the preparation remained clear and free from visible denatured material. The GLC-LDL was dialyzed against 0.15 M NaCI/0.01 % Na^DTA (pH 7.0) to remove unreacted reagents; it was subsequently radioiodinated as described above. The labeled preparation was sterilized by membrane filtration before injection.
Since 2-hydroxyacetaldehyde was much more reactive than glucose, modification of the required number of lysine residues on apo LDL was achieved within an incubation period of 2.5 hours. The incubation mixture contained radioiodinated LDL (3 mg protein/ml), 80 mM 2-hydroxyacetaldehyde, and 80 mM sodium cyanoborohydride. Hydroxyethylated, radioiodinated LDL (HOET-LDL) was then freed of the unbound modifying reagents by filtration through a PD 10 column with 0.15 M NaCI, 0.01% Na-^DTA (pH 7.0) as eluant. The physicochemical properties of the preparation were compared with those of native LDL, as follows:
Lipoprotein Modifications
The arginyl or lysyl residues of one of the labeled tracers was modified as described below. Usually, the 131 I LDL was used for modification; reversing the isotopes did not affect the results obtained.
Arginine Modification
Labeled LDL at a concentration of 2 to 3 mg/ml was incubated in the presence of two volumes of 0.15 M 1,2 cyclohexanedione in 0.2 M borate buffer (pH 8.1) 4 for 2 hours at 35° C. Unreacted CHD was removed by gel filtration through a PD 10 column (Pharmacia, UK) with 0.15 M NaCI/0.01% N^EDTA (ph 7.0) as eluant. The product has been characterized previously. 4610 Immediately after preparation, the labeled modified lipoprotein was sterilized by membrane filtration (0.22 /x filters, Amicon Corporation, Bedford, Massachusetts) and injected into the donor.
Lysine Modifications
The lysine residues on LDL were modified by using either glucose or 2-hydroxyacetaldehyde. Both of these reagents form a Schiff base with the epsilon amino groups of lysine, which can be reduced to a stable product with sodium cyanoborohydride. However, the time taken for this reaction to produce substantial lysine modification (at least 30% modification is required to completely inhibit receptor binding in vitro 5 ) is significantly longer in the case of glucose. Consequently, in the preparation of GLC-LDL, the modification of the lipoprotein preceded its labeling. Approximately 5.0 ml of LDL at a protein concentration of 5.0 mg/ml was passed through a 0.22 fi Amicon filter and incubated under sterile conditions in phosphate-buffered 0.15 M NaCI (pH 7.4) 1. The 2-hydroxyacetaldehyde-treated material retained the flotation properties of unmodified LDL. Consistently more than 90% of the materials' associated radioactivity could be reisolated within the 1.030 to 1.050 kg/liter density interval and was coincident with native LDL on rate zonal ultracentrifugation ( Figure 1 ).
2. The flotation rates of native and HOET-LDL were determined by analytical ultracentrifugation at 26° C and 1.063 kg/liter (NaCI). The values obtained were 5.41 ± 0.27 S and 5.93 ± 0.26 S respectively. That is, chemical modification did not alter this physical parameter. 3. Preparations of native and 2-hydroxyacetaldehyde-treated LDL were examined under the electron microscope after staining with uranyl acetate. The particle diameters did not differ significantly. 4. The HOET-LDL, like CHD-LDL and GLC-LDL, exhibited an increase in electrophoretic mobility in an agarose matrix.
The above modification procedures reproducibly blocked more than 55% of the arginine residues 4 ' 10 and 50% of the lysine groups on apo LDL as determined by amino acid analysis; and also for lysine, by titration with trinitrobenzene sulfonic acid. 5 Treatment with 2-hydroxyacetaldehyde did not change the amino acid profile of apo LDL, except for the position of the lysine peak. The preparations did not compete with native LDL 22 for the membrane receptors on cultured fibroblasts (see Cell Culture Studies). To compare the metabolic properties of these preparations with those of control LDL, parallel incubations were performed for the control lipoprotein in the absence of the modifying agent. were mixed with 20 ml of fresh human plasma and subjected to rate zonal ultracentrifugation. 19 After separation, measurements of the absorbance of the profile at 280 nm (• •) and the radioactivities present across the gradient showed that more than 95% of the radioactivity comigrated with the absorbance peak of LDL.
Cell Culture Studies
The interaction of modified LDL with the high affinity LDL receptors on cultured normal fibroblasts (Flow Laboratories, Irvine, UK) was studied by using standard methodology. 22 The cells were maintained in a humidified incubator (5% CO ? ) at 37° C in basal Eagle's medium (Flow Laboratories) supplemented with fetal calf serum (10%), glutamine (2 mM), nonessential amino acids (1%), NaHCO 3 (20 mM), penicillin (100 U/ml), and streptomycin (100 /i.g/ml). Confluent monolayers were dispersed with 0.5% trypsin/0.02% NajEDTA and transferred to flatbased culture tubes (Flow Laboratories) for experimental use. Nonconfluent cultures grown 48 to 72 hours in medium substituted with 10% lipoproteindeficient serum were used in all experiments. Lipoproteins were removed from the serum by ultracentrifugal flotation (48 hours, 114,000 g, 15° C) followed by dialysis of the infranatant against 0.15 M NaCI/0.01 M Tris HCI (pH 7.4). The LDL degradation assays were performed as outlined by Goldstein et al. 22 Figure 2 shows that HOET-LDL, prepared as described above, failed to compete efficiently with LDL for the high affinity membrane receptors on cultured human fibroblasts.
The catabolism of HOET-LDL was also examined in mouse peritoneal macrophages harvested from unstimulated Balb/c animals. The cells were maintained in the medium just described and were used immediately, without preconditioning. Radiolabeled acetyl LDL was added to the medium at a concentration of 5 fig protein/ml and was competed against unlabeled acetyl LDL, native LDL, HOET-LDL, and reductively methylated LDL 5 at concentrations of 100 /xg protein/ml. Table 2 shows that only acetylated LDL competed effectively with the labeled acetyl LDL tracer. Specifically, HOET-LDL was not recognized by the scavenger receptor present on these cells. The culture contained 125 l-acetyl LDL at a concentration of 5 /xg protein/ml. Unlabeled competitors (100 ^g protein/ ml) were added as outlined above. The rate of formation of iodotyrosine was followed over the next 5 hours (see reference 22). HOET-LDL = hydroxyethylated low density lipoprotein.
'Significantly different from control; p < 0.001.
Turnover Protocol
Approximately 25 piCi (0.5 mg of lipoprotein apoprotein) of the sterilized appropriate control LDL and its modified counterpart were injected via an indwelling catheter into the bloodstream of the donors in rapid sequence, separated by a 2.0 ml bolus of 0.15 M NaCI. Blood samples from fasting donors were collected after 10 minutes and thereafter daily for 14 days. The 125 I and 131 I radioactivities present in 2.0 ml samples of plasma from each time point were measured in a twin-channel gamma spectrometer (Packard Instruments Incorporated, Downer's Grove, Illinois), and a decay curve was constructed for each isotope. This was analyzed by the mathematical procedure of Langer et al. 20 and Matthews 23 on the assumption that the kinetics were adequately defined in a two-compartment model. The decay curve was resolved by computer analysis into two exponential functions (Figure 3 ). The slow exponential, which appeared 5 to 8 days after injection of the tracer, had slope b, and intercept C,, while the faster exponential obtained by curve peeling had slope b 2 and intercept C 2 ( Figure 3 ). These parameters can be combined to provide the following rate constants which describe the transit of radioactivity between compartments:
The standard errors associated with the determinations of b,, b 2 , C,, and C 2 were less than 3%, 5%, 2%, and 4%, respectively, of the mean values for each parameter.
To calculate absolute clearance rates for apo LDL, the plasma concentration of the protein 20 was determined from serial LDL cholesterol measurements 17 and the LDL cholesterol/protein ratio was obtained by analysis 1720 of lipoprotein isolated in the density range 1.019-1.063 kg/liter. 24 The parameter was then calculated as the product of the plasma LDL concentration (in mg/dl), plasma volume (in deciliters, taken to be 4% of the body weight) and the fractional clearance rate.
Statistical comparisons were made between groups of results using Student's t test.
Results
The three groups of healthy volunteers examined in the studies described below had virtually identical plasma and LDL cholesterol levels. The respective values in Groups 1, 2, and 3 for cholesterol were 198 ± 17 mg/dl, 198 ± 29 mg/dl, and 186 ± 28 mg/dl; and for LDL cholesterol were 112 ± 11 mg/dl, 118 ± 29 mg/dl and 108 ± 23 mg/dl. Since these concentrations were so similar and gender has no known effect on LDL metabolism, the direct comparison of the kinetics of the control and the chemically modified LDL between the groups was considered acceptable.
The five subjects in Group 1 (two men, three women) received injections of autologous control and GLC-LDL, both of which had been incubated for 7 days in the presence of the reducing agent. Figure 4 describes the mean ( ± SD) decay curves for both labeled tracers in the group. Each tracer was cleared biexponentially from the plasma and the decay profiles could be resolved by Matthews' kinetic analysis 23 into the parameters shown in Table 3 . The terminal slopes (b,) that appeared after about 6 days were different (p < 0.01) and the fractional clearance rates showed that the glucosylated lipoprotein was cleared, on the average, 49% more slowly than control LDL. Therefore, on the premise that GLC-LDL traces the receptor-independent pathway, it is demonstrable (Table 3 ) that the receptor route accounts for one-half of LDL catabolism. Finally, it should be noted that the calculated percentage of the tracer that was intravascular was the same for both control LDL (60% ± 11%) and GLC-LDL (61% ± 14%).
The subjects in Group 2 received injections of control LDL and HOET-LDL ( Figure 5) . Again, the terminal slopes describing the clearance of these tracers differed substantially (b,, Table 4 ), as reflected in their fractional clearance rates (0.37 ± 0.06 pools/ day for control LDL; 0.19 ± 0.03 pools/day for HOET-LDL). Hence, as for GLC-LDL, these data indicate that about 50% (range, 39%-57%) of LDL catabolism took the receptor route. The intercompartmental distributions of the tracers were not significantly different. We proceeded to measure the 'Graphical constants were obtained from plasma decay curves (see Figure 3) . b, and b 2 are the slopes of the second and first exponentials, respectively. C, and C 2 are the y-axis intercepts of the second and first exponentials, respectively. K,^ is the fractional clearance rate, and % IV is the percentage of intravascular tracer. HOET-LDL = hydroxyethylated low density lipoprotein; FCR = fractional clearance rate. 'Graphical constants were obtained from plasma decay curves ( Figure 3 ). See Table 3 for abbreviations.
pool sizes of apo LDL in the group and used this to calculate the absolute clearance rates of the protein by the receptor and nonreceptor pathways. The values obtained (7.0 ± 1.4 mg/kg/day and 7.4 ± 1.4 mg/kg/day respectively) agreed well with earlier data acquired using CHD LDL 7 in a comparable subject group. Despite the apparent similarities between the results obtained using GLC-LDL and HOET-LDL, they did differ significantly. In Study 1, in which the control and modified tracers had been incubated for 7 days, the fractional clearances were substantially faster than those in Study 2. Since HOET-LDL and CHD-LDL seemed to give comparable results, we examined their simultaneous metabolism in a group of 10 subjects (Study 3). Figure 6 and Table 5 describe the results. The kinetic parameters were virtually indistinguishable, and the terminal slopes (b,) and fractional clearance rates of the tracers were identical.
Discussion
Quantitation of receptor-mediated LDL catabolism in humans is critically dependent on the metabolic properties of the modified lipoprotein used to measure the activity of the receptor-independent pathway. This approach presupposes that chemical treatment of the lipoprotein completely blocks lipoprotein uptake by the receptor without affecting its clearance by other mechanisms. Our initial studies used 1,2 cyclohexanedione as an arginine-modifying agent. We found that 30% to 50% of LDL catabolism occurred by the receptor pathway. The time required to prepare the modified tracer was short, and preliminary investigation showed that the incubation conditions in themselves (in the absence of blocking agent) did not alter the metabolism of the lipoprotein. However, it was difficult to settle beyond doubt the question of the tracer's stability in vivo. 10 Consequently, we and others continue to look for an agent that produces a stably modified lipoprotein exhibiting the essential features described.
Recently, two groups 1525 have reported on their experiences with glucose. They found that coincubation of LDL and glucose under sterile conditions pro- 'Graphical constants were obtained from plasma decay curves (Figure 3 ). See Table 3 for abbreviations.
duced a derivative that is not recognized by the high affinity receptors present on the membranes of cultured fibroblasts. When injected into humans, the modified lipoprotein was cleared from plasma much more slowly than control LDL incubated for the same time in the absence of the sugar. We observed the same phenomenon (Table 3 ) but inspection of the data from the three laboratories makes it clear that there is substantial variation in the values obtained for the plasma fractional clearance rate of glucosylated LDL. While patient selection may play a part, the discrepancies in the data are so great that other factors also seem to be influencing the results. In particular, the methods used to prepare the modified tracer differed significantly in the three studies. The total preparation time was between 5 and 12 days, of which 2 to 7 days involved incubation of the lipoprotein at 37° C in the presence of varying concentrations of reducing agent and sugar. So, it is difficult to make direct comparisons of the results of the three studies, and in the discussion which follows we will emphasize our experiences with LDL glucosylation and compare it with an alternative method of lysine modification using 2-hydroxyacetaldehyde. Despite the fact that both glucose and 2-hydroxyacetaldehyde block LDL lysine residues to give a product that no longer binds to high affinity LDL receptors on cultured fibroblast membranes, the metabolism of these agents was significantly different in vivo (Tables 3 and 4) . Table 6 presents the mean values for the computer-derived slopes and Y-axis intercepts from which the fractional clearance rates of the native and chemically modified lipoproteins were obtained. The fractional rate of catabolism of the glucosylated LDL (Study 1, Table 6 ) was significantly higher than that of its 2-hydroxyacetaldehydetreated counterpart (Study 2). Since the terminal slopes (b,, Figure 3 and Table 6 ) of the decay curves were the same, this difference must be due to the values obtained for b 2 and C 2 which describe the initial rapid plasma decay of the lipoprotein. A similar phenomenon was also responsible for the higher fractional clearance rates for the control LDL in Study 1.
Taken together, these data suggest that a prolonged incubation of LDL at 37° C accelerates its initial clearance from the plasma. To test this, human LDL was incubated for periods of 1 to 7 days at 37° C before determining its plasma clearance in rabbits relative to that of LDL prepared fresh from the same donor. 26 The fractional clearance rate of 7-day incubated material was 3.17 ± 0.55 pools/day vs 1.84 ± 0.35 pools/day for fresh LDL (n = 4, p < 0.01). Thus incubation itself accelerated the catabolism of LDL from the plasma of these animals and again the phenomenon appeared confined to the initial rapid component of the decay curve. These findings are most easily explained by postulating that some of the LDL was altered to a form in which the catabolism was accelerated. This may result from proteolysis during the 37° C incubation. If that is the case, then the nonhomogeneity of the tracer would make the application of Matthew's kinetic analysis inappropriate, since the latter assumes a model containing a single radiolabeled species. Therefore, it would be better to introduce a three-pool model to accurately quantify the apo LDL fractional clearance rate, and the fractional clearance values quoted in Table 3 must be interpreted with caution.
As a result of our experience with glucosylation and recent evidence that the homologous glucosemodified LDL may be immunogenic, 27 we sought an alternative lysine modifying procedure. To achieve this, we substituted 2-hydroxyacetaldehyde for glucose in the incubation procedure. The increased reactivity of this agent reduced the required modification time to 2.5 hours. Control LDL incubated under the same conditions had a mean fractional clearance rate of 0.37 ± 0.06 pools/day, a value similar to that obtained (0.34 ± 0.05 pools/day) for freshly prepared, unincubated lipoprotein. 67 The capillary transfer rates and intercompartmental distribution of HOET-LDL were the same as those of normal LDL; comparison of its fractional clearance rate with that of simultaneously injected control lipoprotein showed that, on average, 50% of the lipoprotein was catabolized by the receptor pathway. This agrees with the data calculated for a group of seven healthy 'Graphical constants were obtained from plasma decay curves (Figure 3 ). See Table 3 for abbreviations.
volunteers injected with native and CHD-LDL. 7 In fact, direct comparison of the clearances of HOET-LDL and CHD-LDL showed that their metabolic properties were indistinguishable ( Figure 6 , Table 5 ). So in this regard, CHD-LDL metabolism seems to differ in humans and in rabbits.
Elsewhere 26 we have shown that in rabbits the fractional clearance rate of the arginine-modified lipoprotein was slightly but significantly faster than that of either reductively methylated or 2-hydroxyacetaldehyde-treated LDL (which are catabolized at identical rates). We ascribed this to differential handling of arginine-and lysine-modified LDL by the reticuloendothelial system of this animal. This difference does not occur in humans (Table 5) , and so the data presented here, with either CHD-LDL or HOET-LDL used as tracers of receptor-independent catabolic mechanisms, are consistent with the conclusion that, in the subjects described in Table 1 , the receptor pathway accounted for 50% of LDL catabolism.
